Scholarlink

Introduction <p>Inflammatory bowel diseases (IBDs) are chronic diseases, including Crohn’s disease (CD) and ulcerative colitis (UC). Given the heterogeneity in disease presentation, treatment responses, and lifestyle impacts associated with IBD, understanding patient preferences is essential to inform patient-centered care. By identifying how patients prioritize different aspects of treatment, physicians can provide more personalized, effective management of IBD.</p> Methods <p>A global targeted literature review search was conducted in MEDLINE and Embase between January&#xa0;1, 2004 and July&#xa0;30, 2024, supplemented by conference abstracts to explore patient preferences on treatment modalities and treatment outcomes in IBD.</p> Results <p>Sixty-two studies were identified that matched inclusion criteria. Across studies, it was identified that patients primarily base their treatment decisions on a hierarchy of three factors: efficacy, safety, and ease of administration. Treatment efficacy was often attributed higher importance than safety/tolerability, with factors “time to response” and “improvement in quality of life (QoL)” ranked highly for consideration by patients. Variations in symptom priorities were noted between patients with UC and CD, with patients with UC prioritizing diarrhea reduction while those with CD focusing on abdominal pain relief. Treatment preferences were influenced by route of administration and the ability to self-administer treatments, illustrating the diversity of patient preferences in IBD. Preference for subcutaneous (SC) over intravenous (IV) administration was noted; however, this preference was often dependent on other factors including dosing frequency, ease of use, and previous treatment experiences.</p> Conclusion <p>Patient treatment preferences in IBD represent a trade-off between many factors. However, preferences are highly individualized based on patient experience; as such, there is a need to promote shared decision-making between patients and physicians. To support this, patients should be equipped with the necessary resources to facilitate informed decision-making and active involvement in discussions with their healthcare providers, ensuring that treatment plans align with their personal values and preferences.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Isabelle Whittle,
  • Eva Brown Hajdukova,
  • Hannah Coles,
  • Natasha Perry,
  • Lisa Perrett,
  • Richard Perry,
  • Kyran Jones

摘要

Introduction

Inflammatory bowel diseases (IBDs) are chronic diseases, including Crohn’s disease (CD) and ulcerative colitis (UC). Given the heterogeneity in disease presentation, treatment responses, and lifestyle impacts associated with IBD, understanding patient preferences is essential to inform patient-centered care. By identifying how patients prioritize different aspects of treatment, physicians can provide more personalized, effective management of IBD.

Methods

A global targeted literature review search was conducted in MEDLINE and Embase between January 1, 2004 and July 30, 2024, supplemented by conference abstracts to explore patient preferences on treatment modalities and treatment outcomes in IBD.

Results

Sixty-two studies were identified that matched inclusion criteria. Across studies, it was identified that patients primarily base their treatment decisions on a hierarchy of three factors: efficacy, safety, and ease of administration. Treatment efficacy was often attributed higher importance than safety/tolerability, with factors “time to response” and “improvement in quality of life (QoL)” ranked highly for consideration by patients. Variations in symptom priorities were noted between patients with UC and CD, with patients with UC prioritizing diarrhea reduction while those with CD focusing on abdominal pain relief. Treatment preferences were influenced by route of administration and the ability to self-administer treatments, illustrating the diversity of patient preferences in IBD. Preference for subcutaneous (SC) over intravenous (IV) administration was noted; however, this preference was often dependent on other factors including dosing frequency, ease of use, and previous treatment experiences.

Conclusion

Patient treatment preferences in IBD represent a trade-off between many factors. However, preferences are highly individualized based on patient experience; as such, there is a need to promote shared decision-making between patients and physicians. To support this, patients should be equipped with the necessary resources to facilitate informed decision-making and active involvement in discussions with their healthcare providers, ensuring that treatment plans align with their personal values and preferences.